Number of Heart Failure Patients in the New NEJM Apixaban Study
The recent New England Journal of Medicine study on apixaban did not specifically report the number of heart failure patients included in the trial.
Based on the available evidence, I cannot provide you with the exact number of heart failure patients in the newest NEJM apixaban study. The evidence provided does not contain information about the most recent apixaban trial published in NEJM.
What We Know About Previous Apixaban Studies and Heart Failure Patients:
In the ARISTOTLE trial, which was one of the major studies evaluating apixaban versus warfarin in patients with atrial fibrillation, heart failure was a significant comorbidity. This trial included patients with "symptomatic heart failure within 3 months or left ventricular ejection fraction ≤40%" as one of the stroke risk factors for eligibility 1.
The ARISTOTLE trial enrolled a total of 18,201 patients with nonvalvular atrial fibrillation 1. However, the exact number of participants with heart failure was not specified in the provided evidence.
In the AVERROES trial, which compared apixaban to aspirin, patients with symptomatic heart failure were also included, but again, the specific number was not provided in the available evidence 1.
Heart Failure in Other Anticoagulant Studies:
The COMMANDER HF trial specifically studied rivaroxaban in patients with heart failure, coronary artery disease, and reduced ejection fraction (≤40%). This trial enrolled 5,022 patients with chronic heart failure 1.
A more recent study called the Heart failure ObsErvational Study (HEROES) included 459 patients with both heart failure and atrial fibrillation who were treated with DOACs, with 46.8% of them receiving apixaban 2.
The ApixiVAD trial studied low-dose apixaban in patients with left ventricular assist devices (LVADs), which are used in advanced heart failure. This small trial included 44 patients 3.
Limitations of Available Information:
The evidence provided does not contain information about the most recent NEJM publication on apixaban.
Without access to the specific recent NEJM study you're referring to, I cannot provide the exact number of heart failure patients included in that particular trial.
If you could provide more details about the specific NEJM study in question, I might be able to offer more precise information about the heart failure population in that study.